Online inquiry

IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8078MR)

This product GTTS-WQ8078MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Dermatomyositis, Nephritis, Atypical hemolytic uremic syndrome (aHUS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001317163.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 727
UniProt ID P01031
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8078MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ621MR IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 7F3com-2H2
GTTS-WQ8379MR IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA aTROP2S7
GTTS-WQ8918MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA IL-1 Trap
GTTS-WQ763MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AB0024
GTTS-WQ14380MR IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA r-hTBP-1
GTTS-WQ4909MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ3702MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY 2287409
GTTS-WQ14215MR IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RG4934
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW